3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Neoplasm Metastasis
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
30
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
tesetaxel
×
Clear all
NCT03326674
2021-07-30
CONTESSA
Odonate Therapeutics, Inc.
Phase 3
Terminated
685 enrolled
NCT03858972
2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2
Terminated
152 enrolled
NCT03952325
2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2
Terminated
294 enrolled